UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Nature communications, 2019-04, Vol.10 (1), p.1812-1812, Article 1812

2019

Volltextzugriff (PDF)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer

Therapeutic advances in medical oncology, 2018-01, Vol.10, p.1758835918763744-1758835918763744

2018

Volltextzugriff (PDF)

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Nature communications, 2017-09, Vol.8 (1), p.410-14, Article 410

2017

Volltextzugriff (PDF)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)

International journal of biological sciences, 2019-01, Vol.15 (12), p.2607-2614

2019

Volltextzugriff (PDF)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Scientific reports, 2023-03, Vol.13 (1), p.3620-3620, Article 3620

2023

Volltextzugriff (PDF)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Scientific reports, 2015-12, Vol.5 (1), p.17499, Article 17499

2015

Volltextzugriff (PDF)

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma

Cell communication and signaling, 2019-10, Vol.17 (1), p.137-137, Article 137

2019

Volltextzugriff (PDF)

RNA secondary structure mediates alternative 3′ss selection in Saccharomyces cerevisiae

RNA (Cambridge), 2012-06, Vol.18 (6), p.1103-1115

2012

Volltextzugriff (PDF)

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines

Translational lung cancer research, 2019-08, Vol.8 (4), p.340-351

2019

Volltextzugriff (PDF)

PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer

Journal of cancer metastasis and treatment, 2019-03, Vol.2019

2019

Volltextzugriff (PDF)

RNA secondary structure mediates alternative 3'ss selection in Saccharomyces cerevisiae

RNA (Cambridge), 2012-06, Vol.18 (6), p.1103-1115

2012

Volltextzugriff (PDF)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

JNCI : Journal of the National Cancer Institute, 2017-09, Vol.109 (9)

2017

Volltextzugriff (PDF)

Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot

Nucleic acids research, 2007-04, Vol.35 (8), p.e60-e60

2007

Volltextzugriff (PDF)

Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer

Clinical lung cancer, 2019-05, Vol.20 (3), p.167-177

2019

Volltextzugriff (PDF)

Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer

Translational lung cancer research, 2019-10, Vol.8 (5), p.667-673

2019

Volltextzugriff (PDF)

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

Oncotarget, 2017-07, Vol.8 (29), p.47305-47316

2017

Volltextzugriff (PDF)

Abstract 3077: Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3077-3077

2017

Volltextzugriff (PDF)

IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKCÎ¹ inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e24001-e24001

2018

Volltextzugriff (PDF)

Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC

Translational lung cancer research, 2018-09, Vol.7 (S3), p.S183-S186

2018

Volltextzugriff (PDF)

Abstract 336: S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.336-336

2016

Volltextzugriff (PDF)

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer

Translational lung cancer research, 2020-10, Vol.9 (5), p.1810-1821

2020

Volltextzugriff (PDF)

P3.01-038 STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1143

2017

Volltextzugriff (PDF)

P1.02-064 MET-Dependent Activation of STAT3 as Mediator of Resistance to MEK Inhibitors in KRAS-Mutant Lung Cancer: Topic: Other Mutations in Thoracic Malignancies

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S527-S527

2017

Volltextzugriff (PDF)

P3.01-038 STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma: Topic: Functional Biology in Lung Cancer

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1143-S1143

2017

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(14)
Humans
(10)
Lung Cancer
(10)
Oncology
(9)
Carcinoma, Non-Small-Cell Lung - Genetics
(7)
Cell Line, Tumor
(7)
Lung Neoplasms - Genetics
(7)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)
Erbb Receptors - Genetics
(6)
Female
(6)
Male
(6)
Resistance
(6)
Aged
(5)
Animals
(5)
Carcinoma, Non-Small-Cell Lung - Pathology
(5)
Lung Neoplasms - Drug Therapy
(5)
Mice
(5)
Middle Aged
(5)
Mutation
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis

RNA secondary structure mediates alternative 3′ss selection in Saccharomyces cerevisiae

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines

PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer

RNA secondary structure mediates alternative 3'ss selection in Saccharomyces cerevisiae

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot

Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer

Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

Abstract 3077: Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR

IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKCÎ¹ inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC)

Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC

Abstract 336: S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer

P3.01-038 STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma

P1.02-064 MET-Dependent Activation of STAT3 as Mediator of Resistance to MEK Inhibitors in KRAS-Mutant Lung Cancer: Topic: Other Mutations in Thoracic Malignancies

P3.01-038 STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma: Topic: Functional Biology in Lung Cancer

Suchergebnisse filtern